Drug Device Combination
Products

The National Medical Products Administration (NMPA) defines drug-device combination products as medical products composed of both drugs and medical devices, integrated into a single entity.

To register a combination product with the NMPA, you must first determine the product’s Primary Mode of Action (PMOA):

Drug-led combination products registration applications must be submitted to the Center for Drug Evaluation (CDE)
Device-led combination products must be submitted to the Center for Medical Device Evaluation (CMDE).

If the device PMOA is unclear, applicants can apply for an attribute definition from the NMPA’s Center for Medical Device Standards Management (CMDSM) before submitting the premarket approval application.

Single entity combination products
Drug products inside delivery device

Joint Evaluation of Drug Device 
Combination Products

During a joint evaluation, the CDE and CMDE collaborate to assess the product's safety, effectiveness, and quality control. Each center issues an evaluation report covering its respective component, and the leading unit consolidates these findings into an overall evaluation report. This report is then submitted to the relevant NMPA department for administrative approval.

For drug-led combination products, the CDE leads the evaluation. If a joint evaluation is required, the application dossier is transferred to the CMDE for synchronized evaluation.

For device-led combination products, the CMDE leads the evaluation. If a joint evaluation is required, the dossier is transferred to the CDE.

During a joint evaluation, the CDE and CMDE collaborate to assess the product's safety, effectiveness, and quality control. Each center issues an evaluation report covering its respective component, and the leading unit consolidates these findings into an overall evaluation report. This report is then submitted to the relevant NMPA department for administrative approval.

Our China Drug-Device Combination Product Services

With expertise in both pharmaceutical and medical device regulations, we assist with the classification, registration and compliance of both drug and device-led combination products.

Our services include:

Regulatory Pathway Assessment

If uncertain, we assist in applying for an attribute definition with the Center for Medical Device Standards Management (CMDSM).
Determine the product’s primary mode of action (PMOA) to classify it as drug-led or device-led.

Registration Strategy Development

Develop a customized regulatory strategy aligned with the requirements of the Center for Drug Evaluation (CDE) or the Center for Medical Device Evaluation (CMDE), depending on the product’s classification.
Coordinate with both centers for joint evaluations as required.

Dossier Preparation & Submission

Ensure that documentation covers both drug and device components, including safety, efficacy, and quality control data including the necessary type testing in China.
Prepare and compile the registration dossier, ensuring compliance with NMPA guidelines.
Submit the application through the NMPA online platform.

Clinical Trial Application (CTA)

Ensure compliance with Good Clinical Practice (GCP) standards for both drug and device components.
Assist in obtaining approval for clinical trials if required.

Communication & Coordination with Regulatory Authorities

Liaise with the CDE and CMDE to facilitate the evaluation process.
Address enquiries and provide additional documentation as requested by regulators.

Post-Approval Compliance

Ensure compliance with post-market surveillance requirements, including pharmacovigilance and medical device vigilance.
Support registration renewals, variations, and amendments.

Request a Proposal from Our Life Sciences Team about Your Combination Product

Let Cisema help turn your plans into reality.

Angebot anfordern

Useful Articles

View More

A Guide to Dossier Preparation for Indonesia Medical Device Registration

Discover the documents required for Indonesia medical device and IVD registration, including dossier requirements, legalization, submission and common FAQs.

August 3, 2026
A Guide to Dossier Preparation for Indonesia Medical Device Registration
Stock photograph of an Indonesian adult man performing a routine blood glucose test at home, one hand holding a blue handheld blood glucose meter with a test strip inserted while the other hand gently presents an index finger

A Complete Guide to China Hyaluronic Acid Registration

A complete guide to China hyaluronic acid registration, covering classification, NMPA requirements, and compliance steps for manufacturers.

August 3, 2026
A Complete Guide to China Hyaluronic Acid Registration

A Practical Guide to Medical Device Registration in Indonesia

Learn how to register medical devices in Indonesia, including Authorized Representative rules, classification, dossiers, timelines, and fees.

August 3, 2026
A Practical Guide to Medical Device Registration in Indonesia
Three masked surgical staff in green operating room attire stand with folded arms beside a patient lying on an operating table, with medical monitors and X-ray images displayed in a dimly lit operating room.”

What Is the MFDS? Understanding South Korea’s Medical Device Authority

Learn how South Korea’s Ministry of Food and Drug Safety regulates medical devices, including classification, application review and post-market duties.

August 3, 2026
What Is the MFDS? Understanding South Korea’s Medical Device Authority

A Guide to South Korea Medical Device Regulation for Global Manufacturers

Understand South Korea’s medical device regulations, from classification to approval and post-market compliance.

August 3, 2026
A Guide to South Korea Medical Device Regulation for Global Manufacturers

China NMPA Fee Catalogue for Drugs & Medical Devices

Learn the latest China NMPA registration fees for imported and domestic drugs and medical devices.

August 3, 2026
China NMPA Fee Catalogue for Drugs & Medical Devices
Previous
Previous

Explore Related Services

Whether you’re just starting out or are a blue-chip, access our wide range of services and solutions to help your business thrive.

Pharmaceutical Development & Strategy Consulting

We assess your product’s market viability and identify development gaps to enhance readiness. We create tailored regulatory and clinical strategies aligned with Chinese health authority requirements, ensuring clear and compliant communication for streamlined approval.

Mehr erfahren

China Clinical Trials

You may be required to provide supplementary clinical data on Chinese patients or conduct a full clinical trial in China.Our clinical research team will advise you, prepare the study protocol and assist setting up the clinical trial in China.

Mehr erfahren

China Medical Device Registration

We guide you through every step of the China medical device registration and filing process. We take care of compliance with NMPA requirements, advising you on the optimal market entry pathway, and helping you through the whole process.

Mehr erfahren

NMPA Clinical Evaluation Report

Clinical Evaluation Reports can avoid the need for a China clinical trial in some instances. Our experts can advise and prepare NMPA compliant CERs.

Mehr erfahren

NMPA Legal Agent

We are your authorized representative in China, and fulfill your registrations and filings as well as ensuring compliance with quality and PMS requirements.

Mehr erfahren

China Medical Device Quality Compliance

We help you achieve and ensure ongoing compliance with Chinese requirements.Our experts prepare and assist you for official NMPA inspections.

Mehr erfahren

Medical Device PMS & Vigilance

The NMPA is placing greater focus on Post-Market Surveillance (PMS) such as more in-market sampling inspections and regular standard changes.Our specialist PMS team means you stay up to date with the many aspects of compliance.

Mehr erfahren

Regulatory Outsourcing

If you are seeking specific specialist expertise or have ongoing resource-intensive needs, we have a variety of solutions to meet your needs.

Mehr erfahren

NMPA Type Testing

Our on-site test engineers coordinate and supervise type tests of your medical devices in NMPA-accredited laboratories.

Mehr erfahren

Aktuelle Einblicke

Mehr anzeigen

Hong Kong Introduces Measures for Priority Approval of Innovative Medical Devices

Updated MDACS guidance creates a new pathway for qualifying technologies and outlines the evidence required for priority consideration.

August 3, 2026
Hong Kong Introduces Measures for Priority Approval of Innovative Medical Devices

CDE Releases 2025 Annual Report on the Progress of Clinical Trials for New Drug Registration in China

Explore the latest data on China’s clinical research landscape, including record trial activity, shorter development timelines, and emerging R&D trends.

August 3, 2026
CDE Releases 2025 Annual Report on the Progress of Clinical Trials for New Drug Registration in China

China Targets 65 Drugs in Its 12th National Procurement Round

The 12th national VBP round introduces tighter quality, manufacturing, and IP requirements that pharmaceutical companies must meet to compete.

August 3, 2026
China Targets 65 Drugs in Its 12th National Procurement Round

China CDE Defines Classification Rules for Cell & Gene Therapy Drugs

New NMPA CDE guidelines define CTMP and GTMP boundaries, affecting development strategy, CMC planning, and regulatory engagement in China.

August 3, 2026
China CDE Defines Classification Rules for Cell & Gene Therapy Drugs

China's 2026 Essential Medicines Adds More Innovative Drugs

China's updated National Essential Medicines List expands access to innovative medicines, creating new opportunities and strategic considerations for pharmaceutical companies.

August 3, 2026
China's 2026 Essential Medicines Adds More Innovative Drugs
A middle-aged man with glasses is looking down thoughtfully as he pours medication or pills from a small white bottle with a yellow label into his open palm.

China NMPA Expands Priority Review for Chemical API Marketing Authorization Applications

China's NMPA expands priority review eligibility for chemical API marketing authorization applications, supporting domestic API production and drug supply.

August 3, 2026
China NMPA Expands Priority Review for Chemical API Marketing Authorization Applications
Chemical API Manufacturing
Zurück
Zurück

Get in Touch with Our Life Sciences Team

And discover how we can support you in achieving approval for your drug-device combination product in China.

Angebot anfordern